-
Article
Open AccessSurvival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patien...
-
Article
Open AccessDurable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
-
Article
Open AccessObservational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.
-
Article
Open AccessFibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of pa...
-
Chapter
Bortezomib in Mantle Cell Lymphoma
Since its recognition as a separate subtype of non-Hodgkin lymphoma (NHL) in 1994, mantle cell lymphoma (MCL) has been a very active field of clinical research due to its typical poor outcome. Besides a small ...